Scope of the Report
The report titled “Global Allergy Immunotherapy Market (2018-2022 Edition)”, provides an in-depth analysis of the global allergy immunotherapy market by value, by methods of administration, by region, etc. The report provides a regional analysis of the allergy immunotherapy market, including the following regions: the US, Europe and Rest of the World.

Growth of the overall global allergy immunotherapy market has also been forecasted for the period 2018-2022, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

The key players of the allergy immunotherapy market ALK-Abello, Allergy Therapeutics, Merck Group and Stallergenes, who are also profiled with their financial information and respective business strategies.

Country Coverage

  • The US
  • Europe
  • Rest of the World

Company Coverage

  • ALK-Abello
  • Allergy Therapeutics
  • Merck Group
  • Stallergenes

Executive Summary
Allergen immunotherapy, also known as “allergy shots”, is a form of long-term treatment that decreases symptoms for many people with allergic rhinitis, allergic asthma, conjunctivitis (eye allergy) or stinging insect allergy. Immunotherapy involves exposing people to larger and larger amounts of allergen in an affect to change the immune system’s response. Allergy immunotherapy is an established treatment for severe allergies such as allergic rhinitis and allergic asthma. The allergy immunotherapy can be classified on the basis of method of administration: subcutaneous (SCIT), sublingual (SLIT-tablets/drops) and whole allergen.

The global allergy immunotherapy market has increased at a significant CAGR during the years 2013-2017 and projections are made that the market would rise in the next four years i.e. 2018-2022 tremendously. The allergy immunotherapy market is expected to increase due to growth in healthcare expenditure, rising incidence of chronic diseases and increasing global pollution, etc. Yet the market faces some challenges such as, lack of treatment awareness, lack of investor confidence, anaphylaxia, huge treatment costs, etc.